Wall Street Zen Upgrades Adagene (NASDAQ:ADAG) to “Hold”

Adagene (NASDAQ:ADAG – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

ADAG has been the subject of a number of other research reports. Stifel Nicolaus set a $7.00 price target on shares of Adagene in a research report on Monday, October 19th. Chardan Capital reissued a “buy” rating and issued a $9.00 target price on shares of Adagene in a research report on Wednesday, October 28th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Adagene in a research report on Monday, October 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adagene in a research note on Thursday, October 15th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.25.

View Our Latest Stock Report on ADAG

Adagene Price Performance

NASDAQ:ADAG opened at $1.76 on Friday. Adagene has a 1-year low of $1.27 and a 1-year high of $4.85. The firm has a 50-day moving average of $2.55 and a two-hundred day moving average of $3.38.

Insider Buying and Selling at Adagene

In related news, CEO Peter Luo bought 20,290 shares of Adagene stock in a transaction that occurred on Wednesday, September 16th. The stock was purchased at an average cost of $3.15 per share, for a total transaction of $63,913.50. Following the acquisition, the chief executive officer owned 88,535 shares in the company, valued at $278,885.25. This trade represents a 29.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 21.20% of the company’s stock.

Hedge Funds Weigh In On Adagene

Several large investors have recently added to or reduced their stakes in the company. State Street Corp acquired a new stake in Adagene during the third quarter worth $88,000. Renaissance Technologies LLC bought a new stake in Adagene in the 1st quarter valued at $135,000. Marshall Wace LLP raised its stake in shares of Adagene by 554.6% in the 3rd quarter. Marshall Wace LLP now owns 452,310 shares of the company’s stock valued at $1,447,000 after buying an additional 383,210 shares in the last quarter. Finally, Flputnam Investment Management Co. acquired a new position in shares of Adagene in the 3rd quarter valued at $2,183,000. Institutional investors and hedge funds own 9.51% of the company’s stock.

About Adagene

(Get Free Report)

Adagene Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based cancer immunotherapies. Its research combines computational protein-design methods with antibody engineering to create treatments intended to target tumors and engage the immune system. The company’s technologies include its SAFEbody platform, which is designed to keep an antibody’s activity masked until it reaches the tumor environment. Adagene is also developing antibody candidates that target immune-regulatory pathways, including CTLA-4, for potential use in cancer treatment.

Read More

Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.